HPS-173 - Evaluation of steady-state exposure and early cardiotoxicity in Asian patients with HER2-positive breast cancer treated with trastuzumab

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-173
• By: JIANG, Shuai (Harbin Medical University Cancer Hospital, China)
• Co-author(s): Prof Shuai Jiang (Harbin Medical University Cancer Hospital, Harbin, China)
  Prof Mei Dong (Harbin Medical University Cancer Hospital, Harbin, China)
  
• Abstract:

  Background: Breast cancer is one of the most common malignant tumors among women worldwide. HER2-positive breast cancer, in particular, is a highly aggressive subtype, with patients facing a higher risk of recurrence and metastasis, as well as relatively poor prognosis. Currently, trastuzumab has been approved for the targeted therapy of patients..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login